Yifan Zhai, M.D., Ph.D.

Trials

Studies that name Yifan Zhai, M.D., Ph.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:44 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05147467 · Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

  Ascentage Pharma Group Inc. · recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · study director
• Ph1/Ph2
  NCT04501120 · Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

  Ascentage Pharma Group Inc. · recruiting · Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy · study director
• Ph1/Ph2
  NCT04494503 · Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

  Ascentage Pharma Group Inc. · recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · study director
• Ph1/Ph2
  NCT04284488 · Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

  Ascentage Pharma Group Inc. · terminated · Advanced Solid Tumor · study director
• Ph1
  NCT03585322 · APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

  Ascentage Pharma Group Inc. · completed · Chronic Hepatitis B · study director
• Ph1
  NCT03387332 · APG-1252 in Patients With SCLC or Advanced Solid Tumors

  Ascentage Pharma Group Inc. · terminated · Small Cell Lung Cancer and Other Solid Tumors · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.